Breast cancer   pipeline review h1 2013 - Reports Corner
Upcoming SlideShare
Loading in...5
×
 

Breast cancer pipeline review h1 2013 - Reports Corner

on

  • 408 views

Global Markets Direct's, 'Breast Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for ...

Global Markets Direct's, 'Breast Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects.

https://www.reportscorner.com/reports/15403/Breast-Cancer---Pipeline-Review,-H1-2013/

Statistics

Views

Total Views
408
Views on SlideShare
408
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Breast cancer   pipeline review h1 2013 - Reports Corner Breast cancer pipeline review h1 2013 - Reports Corner Presentation Transcript

  • RCReports CornerBreast Cancer - Pipeline Review, H1 2013
  • DescriptionDescriptionReports Cornerwww.reportscorner.comGlobal Markets Directs, Breast Cancer - Pipeline Review, H12013, provides an overview of the indications therapeuticpipeline. This report provides information on the therapeuticdevelopment for Breast Cancer, complete with latest updates, andspecial features on late-stage and discontinued projects.
  • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comGlobal Markets Directs, Breast Cancer - Pipeline Review, H12013, provides an overview of the indications therapeuticpipeline. This report provides information on the therapeuticdevelopment for Breast Cancer, complete with latest updates, andspecial features on late-stage and discontinued projects. It alsoreviews key players involved in the therapeutic development forBreast Cancer. Breast Cancer - Pipeline Review, Half Year is builtusing data and information sourced from Global Markets Directsproprietary databases, Company/University websites, SEC filings,investor presentations and featured press releases fromcompany/university sites and industry-specific third partysources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or alteredbased on the availability and relevance of data for the indicateddisease.
  • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comScope- A snapshot of the global therapeutic scenario for Breast Cancer.- A review of the Breast Cancer products under development bycompanies and universities/research institutes based oninformation derived from company and industry-specific sources.- Coverage of products based on various stages of developmentranging from discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy andcombined therapeutics.- Coverage of the Breast Cancer pipeline on the basis of route ofadministration and molecule type.- Key discontinued pipeline projects.- Latest news and deals relating to the products.
  • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comReasons to buy- Identify and understand important and diverse types oftherapeutics under development for Breast Cancer.- Identify emerging players with potentially strong productportfolio and design effective counter-strategies to gaincompetitive advantage.- Plan mergers and acquisitions effectively by identifying playersof the most promising pipeline.- Devise corrective measures for pipeline projects byunderstanding Breast Cancer pipeline depth and focus ofIndication therapeutics.- Develop and design in-licensing and out-licensing strategies byidentifying prospective partners with the most attractive projectsto enhance and expand business potential and scope.- Modify the therapeutic portfolio by identifying discontinuedprojects and understanding the factors that drove them frompipeline.
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comTable of ContentsTable of Contents 2Introduction 12Breast Cancer Overview 13Therapeutics Development 14Breast Cancer Therapeutics under Development by Companies 16Breast Cancer Therapeutics under Investigation by Universities/Institutes 37Late Stage Products 44Mid Clinical Stage Products 45Early Clinical Stage Products 46Discovery and Pre-Clinical Stage Products 47Breast Cancer Therapeutics - Products under Development by Companies 48Breast Cancer Therapeutics - Products under Investigation by Universities/Institutes 83Companies Involved in Breast Cancer Therapeutics Development 91Breast Cancer - Therapeutics Assessment 335
  • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comDrug Profiles 343Breast Cancer Therapeutics - Drug Profile Updates 423Breast Cancer Therapeutics - Discontinued Products 469Breast Cancer Therapeutics - Dormant Products 477Breast Cancer - Product Development Milestones 505Appendix 513
  • For more informationFor more informationReports Cornerwww.reportscorner.comFor more information please visit our websitehttps://www.reportscorner.com/reports/15403/Breast-Cancer---Pipeline-Review,-H1-2013/
  • Reports CornerThank YouThank Youwww.reportscorner.comRCContact us: contact@reportscorner.com
  • Reports CornerThank YouThank Youwww.reportscorner.comRCContact us: contact@reportscorner.com